share_log

Abbott Laboratories | 8-K: Abbott Reports Second-Quarter 2024 Results and Raises Full-Year Guidance

Abbott Laboratories | 8-K: Abbott Reports Second-Quarter 2024 Results and Raises Full-Year Guidance

雅培 | 8-K：雅培公布2024年第二季度业绩并上调全年预期
美股SEC公告 ·  2024/07/18 19:41

Moomoo AI 已提取核心信息

Abbott reported Q2 2024 sales of $10.4 billion, up 4.0% year-over-year, with organic sales growth of 9.3% for the underlying base business. Diluted EPS was $0.74 GAAP and $1.14 adjusted. Medical Devices led growth with 12.1% organic increase, driven by Diabetes Care and Electrophysiology.The company raised its full-year 2024 EPS guidance, now projecting $3.30-$3.40 GAAP and $4.61-$4.71 adjusted. Abbott also narrowed its organic sales growth guidance for the base business to 9.5-10.0%. Key product approvals in Q2 included the Esprit BTK system for peripheral artery disease and two new over-the-counter continuous glucose monitoring systems.Abbott's strong Q2 performance was supported by double-digit growth in FreeStyle Libre sales, which reached $1.6 billion. The company continues to strengthen its portfolio through new product launches and approvals, positioning itself for sustained growth.
Abbott reported Q2 2024 sales of $10.4 billion, up 4.0% year-over-year, with organic sales growth of 9.3% for the underlying base business. Diluted EPS was $0.74 GAAP and $1.14 adjusted. Medical Devices led growth with 12.1% organic increase, driven by Diabetes Care and Electrophysiology.The company raised its full-year 2024 EPS guidance, now projecting $3.30-$3.40 GAAP and $4.61-$4.71 adjusted. Abbott also narrowed its organic sales growth guidance for the base business to 9.5-10.0%. Key product approvals in Q2 included the Esprit BTK system for peripheral artery disease and two new over-the-counter continuous glucose monitoring systems.Abbott's strong Q2 performance was supported by double-digit growth in FreeStyle Libre sales, which reached $1.6 billion. The company continues to strengthen its portfolio through new product launches and approvals, positioning itself for sustained growth.
雅培报告2024年第二季度销售额为104亿美元，同比增长4.0%，基础业务的有机销售增长为9.3%。摊薄后每股收益为0.74美元（GAAP）和1.14美元（调整后）。医疗设备以12.1%的有机增长领先，主要得益于糖尿病护理和心电生理学。公司提高了全年2024年每股收益指导，现预计GAAP为3.30-3.40美元，调整后为4.61-4.71美元。雅培还将基础业务的有机销售增长指导范围缩小至9.5-10.0%。第二季度的关键产品审批包括用于外周动脉疾病的Esprit BTk系统和两种新的非处方连续血糖监测系统。雅培第二季度的强劲表现得益于FreeStyle Libre销售的两位数增长，销售额达到了16亿美元。公司继续通过新产品推出和审批来加强其产品组合，为持续增长做好准备。
雅培报告2024年第二季度销售额为104亿美元，同比增长4.0%，基础业务的有机销售增长为9.3%。摊薄后每股收益为0.74美元（GAAP）和1.14美元（调整后）。医疗设备以12.1%的有机增长领先，主要得益于糖尿病护理和心电生理学。公司提高了全年2024年每股收益指导，现预计GAAP为3.30-3.40美元，调整后为4.61-4.71美元。雅培还将基础业务的有机销售增长指导范围缩小至9.5-10.0%。第二季度的关键产品审批包括用于外周动脉疾病的Esprit BTk系统和两种新的非处方连续血糖监测系统。雅培第二季度的强劲表现得益于FreeStyle Libre销售的两位数增长，销售额达到了16亿美元。公司继续通过新产品推出和审批来加强其产品组合，为持续增长做好准备。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间